Cost-effectiveness analysis of ceftazidime avibactam versus colistin in carbapenem-resistant enterobacteriaceae in Iran

Table 1 Model inputs, ranges used in one-way sensitivity analyses, and distributions applied in probabilistic sensitivity analysis

Parameter	Value	Value lower 95% CI	Value upper 95% CI	Distribution	Source or justification
Mean age of patients	61	NA	NA	Not varied	[12]
Model time horizon	5 years	NA	NA	Not varied	[7]
Efficacy and complication for CA^a
Cure	0.129	0.1	0.155	Beta	[12]
Mortality at day 28	0.09	0.076	0.11	Beta	[12]
Nephrotoxicity	0.05	0.04	0.06	Beta	[12]
RRT	0.04	0.03	0.05	Beta	[12]
Discharge to home	0.559	0.44	0.67	Beta	[12]
Efficacy and complication for COL^b
Cure	0.07	0.056	0.084	Beta	[12]
Mortality at day 28	0.25	0.2	0.3	Beta	[12]
Nephrotoxicity	0.13	0.1	0.156	Beta	[12]
RRT	0.11	0.08	0.132	Beta	[12]
Discharge to home	0.23	0.156	0.276	Beta	[12]
Total cost
CA based therapy	649	519	778	Gamma	Tariff^e of Iran's HS^f
Col based therapy	445	356	534	Gamma	Tariff of Iran's HS
Treatment failure	808	646	969	Gamma	Tariff of Iran's HS
NTX^c with RRT^d	9764	7811	11718	Gamma	Tariff of Iran's HS
NTX without RRT	901	720	1081	Gamma	Tariff of Iran's HS
Long term care	598	478	717	Gamma	Tariff of Iran's HS
Utility
Cure	0.84	0.756	0.924	Beta	[7]
No cure	0.73	0.657	0.803	Beta	[7]
Nephrotoxicity	0.66	0.594	0.726	Beta	[7]
Long-term care	0.64	0.576	0.704	Beta	[7]
Chronic dialysis	0.59	0.531	0.649	Beta	[7]
Discount rate
Cost	0.058	NA	NA	Not varied	[22]
QALY	0.03	NA	NA	Not varied	[22]

a: ceftazidime-avibactam, b: colistin, c: nephrotoxicity, d: renal replacement therapy, e: https://ta.muq.ac.ir, f:health system

ISSN: 1478-7547